Cullinan Management CGEM 深 沪
等待开盘 09-06 09:30:00 美东时间
6.99
+0.080
+1.16%
华盛通- 最 高7.15
- 今 开6.88
- 成交量 74.06万股
- 最 低 6.85
- 昨 收 6.91
- 总市值 4.13亿
- 52周最高 18.6199
- 市盈率 静 --
- 换手率 1.25%
- 52周最低 6.61
- 委 比 -86.48%
- 总股本 5907.44万
- 历史最高 59.85
- 量 比 1.28
- 振 幅 4.34%
- 历史最低 6.61
- 每 手 1
- 风险率 3.48%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Cullinan Therapeutics to Participate in Upcoming Investor Conferences
Cullinan Therapeutics, Inc. (Nasdaq: CGEM) announced its participation in two upcoming investor conferences. CEO Nadim Ahmed and CMO Jeffrey Jones will attend the Cantor Global Healthcare Conference 2025 in New York on September 4, 2025, and the Morgan Stanley Global Healthcare Conference in New York on September 10, 2025. Webcasts of the fireside chats will be available on the company’s investor relations website. Cullinan, a biopharmaceutical c...
08-21 20:05
Morgan Stanley Maintains Overweight on Cullinan Therapeutics, Lowers Price Target to $28
Morgan Stanley analyst Jeffrey Hung maintains Cullinan Therapeutics (NASDAQ:CGEM) with a Overweight and lowers the price target from $35 to $28.
08-18 21:12
Cullinan Therapeutics Q2 EPS $(1.07) Misses $(0.84) Estimate
Cullinan Therapeutics (NASDAQ:CGEM) reported quarterly losses of $(1.07) per share which missed the analyst consensus estimate of $(0.84) by 26.93 percent. This is a 57.35 percent decrease over losses of $(0.68) per
08-07 19:18
Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results
Cullinan Therapeutics reported updates on its CLN-978 program across three Phase 1 studies in systemic lupus erythematosus, rheumatoid arthritis, and Sjögren’s disease, and the in-licensing of velinotamig, a BCMA-directed bispecific T cell engager. The company also shared pivotal results for zipalertinib at ASCO 2025 and announced the appointment of Mittie Doyle and Andrew Allen to its Board of Directors. Financially, the company ended Q2 2025 wi...
08-07 11:00
美股大行评级 | GitLab遭多家大行下调目标价！Stifel首予优步"买入"评级，目标价110美元
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1139839943846023169.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Loop Capital：维持Dave & Buster's Enter(PLAY)"买入"评级，目标价从35美元升至46美元</p> <p>• Stifel：维持嘉年华(CCL)"买入"评级，目标价从31美元升至
06-12 09:46
Stifel Reinstates Buy on Cullinan Therapeutics, Announces $22 Price Target
Stifel analyst Alex Thompson reinstates Cullinan Therapeutics (NASDAQ:CGEM) with a Buy and announces $22 price target.
06-11 23:48
思诺金医药助力智翔金泰与Cullinan就BCMA/CD3项目达成超7亿美元海外授权合作协议
在本次独家许可交易中，思诺金医药任智翔金泰的BD顾问，提供了全程商务服务。 本文为IPO早知道原创 作者｜Stone Jin 微信公众号｜ipozaozhi...
06-05 20:53
思诺金医药助力智翔金泰与Cullinan就BCMA/CD3（GR1803）项目达成超7亿美元海外授权合作协议
原标题：思诺金医药助力智翔金泰与Cullinan就BCMA/CD3（GR1803）项目达成超7亿美元海外授权合作协议 来源：投资界综合 6月5日，智翔金泰（...
06-05 17:00
智翔金泰：与Cullinan就GR1803注射液签署授权许可与商业化协议
6月5日，智翔金泰（688443）公告称，公司与Cullinan Therapeutics, Inc.（纳斯达克股票代码：CGEM；以下简称“Cullinan”）签署授权许可与商业化协议，就GR1803注射液达成独家许可与合作协议。根据协议，Cullinan将获得GR1803 注射液除大中华区域以外区域的开发、生产、商业化权益，智翔金泰保留大中华区域所有适应症权益。
06-05 10:00
